Comparison of the Consequences of Intratracheal Administration of Surfactant Plus Budesonide with Surfactant alone in Preterm Infants with Respiratory Distress Syndrome

To control complications in infants with respiratory distress syndrome, surfactants and auxiliary drugs such as budesonide are used to reduce the inflammatory reactions of the airways. The aim of this study is to compare the effect of intratracheal administration of survanta and survanta with budesonide in premature infants with respiratory distress syndrome.

This clinical trial included 50 premature infants with respiratory distress syndrome, hospitalized in the neonatal intensive care unit in Qazvin Children's Hospital, in 2019. The patients were divided into two groups. One group (25 cases) received intratracheal survanta (1 milliliter) + budesonide (0.25 milligram) and the other group (25 cases) received only intratracheal survanta. Using SPSS 21 software, data were analyzed by  descriptive statistics, Fisher's exact and T-test (p<0.05).

In the survanta+budesonide group, we found intraventricular hemorrhage in 50% and also death in 50% of the cases. In the pregnant women over 31 years of age and female infants receiving survanta + budesonide, no complications were seen. The effect of Survanta + budesonide compared to survanta on reducing complications in the infants (p = 0.048), in regard to the mothers' age group; 31 years and under 31 years (p = 0.049), and over 31 years of age (p = 0.046), female (p=0.047) and male (p=0.050) showed  significant differences.

Administering survanta with budesonide resulted in better efficacy and fewer side effects. Budesonide can be used as an adjuvant treatment. Appropriate therapeutic measures are important for the improvement and survival of the newborns with respiratory distress syndrome.